53 results on '"Candoni, Anna"'
Search Results
2. Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study
3. Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study
4. Reduced prophylactic effect of tixagevimab–cilgavimab in patients with hematological malignancies and without antibody response after SARS‐COV‐2 vaccination
5. The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study
6. PROSPECTIVE MULTICENTER STUDY ON INFECTIOUS COMPLICATIONS AND CLINICAL OUTCOME OF 230 UNFIT ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING FIRST‐LINE THERAPY WITH HYPOMETHYLATING AGENTS ALONE OR IN COMBINATION WITH VENETOCLAX
7. SARS‐CoV‐2 infection and vaccination in patients with hairy‐cell leukaemia
8. Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front‐line with paediatric‐inspired regimens: A retrospective multicentre Campus ALL study
9. Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID‐19: The GIMEMA EMATO‐0321 study
10. Seroconversion and kinetic of anti SARS‐COV‐2 antibodies in 25 patients with hematological malignancies who recovered from SARS‐COV‐2 infection
11. Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric‐like GIMEMA LAL ‐1308 trial
12. Screening procedure for SARS‐CoV‐2 infection combining triage, nasopharyngeal swab and serological test in allogeneic stem cell transplantation recipients undergoing outpatient posttransplant follow‐up
13. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T‐cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study
14. Impact of invasive aspergillosis occurring during first induction therapy on outcome of acute myeloid leukaemia (SEIFEM‐12B study)
15. Philadelphia‐positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID‐19 pandemic: a Campus ALL study
16. Central nervous system fungal infections in allogeneic stem cell transplantation. Outcome of 24 recent cases and literature review
17. Real‐world experience with decitabine as a first‐line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy
18. Co‐administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed‐released tablets in adult patients with haematological malignancies
19. Flai (fludarabine, cytarabine, idarubicin) plus low‐dose Gemtuzumab Ozogamicin as induction therapy in CD33‐positive AML: Final results and long term outcome of a phase II multicenter clinical trial
20. Concomitant monitoring of WT1 and FLT3‐ITD expression in FLT3‐ITD acute myeloid leukemia patients: which should we trust as a minimal residual disease marker?
21. Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers
22. Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy
23. Complex karyotype, older age, and reduced first‐line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long‐term follow‐up
24. Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias
25. Complete and long‐lasting cytologic and molecular remission of FIP1L1‐PDGFRA‐positive acute eosinophil myeloid leukaemia, treated with low‐dose imatinib monotherapy
26. A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients
27. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia
28. JAK2V617F mutation persists in blasts and mature cells of transformedJAK2V617F-positive-myeloproliferative neoplasia: A European leukemia net (ENL) study
29. FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience
30. Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry
31. Quantitative assessment ofWT1gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia
32. Liposomal daunorubicinversusstandard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia
33. Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk?
34. Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases
35. Brain natriuretic peptide level as marker of cardiac function in imatinib—Treated chronic myeloid leukemia patients: No evidence of cardiotoxicity of imatinib therapy
36. Extramedullary progression of multiple myeloma under thalidomide therapy despite concomitant response of medullary disease
37. Case?control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients
38. The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype
39. Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance‐related proteins
40. Leukaemic infiltration of the retina at onset of Philadelphia-positive acute lymphoblastic leukaemia revealed by stratus optical coherence tomography
41. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients
42. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies
43. Atypical haemolytic-uraemic syndrome at the onset of acute promyelocytic leukaemia
44. Biological and clinical features of T‐biphenotypic acute leukaemia: report from a single centre
45. Antibody binding capacity for evaluation of MDR‐related proteins in acute promyelocytic leukemia: Onset versus relapse expression
46. Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia
47. Endogenous endophthalmitis following disseminated fungemia due to Fusarium solani in a patient with acute myeloid leukemia
48. Pregnancy and abortion in women with essential thrombocythemia
49. Pseudomonas pickettii (Biovar VA‐II): a rare cause of bacteremias in haematologic patients
50. Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.